TOOL TO ADJUST FOR SOURCE DECAY IN VACULAR IRRADIATION

调整真空辐射源衰减的工具

• 批准号: 2645513
• 负责人: JOHN R WARD
• 金额: $ 7.95万
• 依托单位: RADIO PROGRAMMES CORPORATION
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-06-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2645513
• 关键词: artificial intelligence; catheterization; cell line; clearance rate; computer assisted medical decision making; computer program /software; computer system design /evaluation; intravenous administration; pharmacokinetics; radiation therapy dosage

In the US, almost 400,000 patients annually receive balloon angioplasty to improve arterial blood flow. About 40 percent of these procedures are unsuccessful because of restenosis, which is estimated to cost the US health care system approximately 0.8-2 billion dollars annually. Endo-vascular irradiation is a new and innovative approach offering the potential of effective restenosis prevention. Almost all the used/proposed radionuclides have short radioactive half- lives so that, during the useful life of the source, exposure times must be continuously extended because of the decreasing source activity. Since the exposure times are comparable to the half-time of sublethal damage repair (T1/2), the biological effect of a given dose will vary significantly over the practical lifetime of the source. The goal is to produce a reliable user-friendly software tool allowing the physician to find the optimal way to adjust for a given reduction in the activity (and therefore the dose rate) of the source, so that the biological effect will remain unchanged. The basic information required is the T1/2 of the target cells, together with the other relevant radiobiological response parameter (alpha/beta). In Phase I, these will be determined for one coronary artery smooth muscle cell line of human origin, and a pilot computer program will be written and assessed, to adjust exposure times to obtain a constant biologically effective dose as the radioactive source decays and treatment times vary. PROPOSED COMMERCIAL APPLICATION Restenosis costs the US health care system approximately 0.8-2 billion dollars/yr. Vascular irradiation is a new technique potentially offering effective restenosis prevention, and is likely to have widespread application. Because the radioactive sources used decay over their useful lifetime, a flexible tool giving biologically-based adjustments in the dose prescription for changes in dose rate will be essential.

在美国，每年将近40万名患者接受气球血管成形术 改善动脉血流。 这些程序中约有40％ 由于再狭窄而没有成功，据估计， 美国医疗保健系统每年约8-2亿美元。 内血管照射是一种新的创新方法，可提供 有效预防病的潜力。 几乎所有使用/提议的放射性核素的放射性半核素都有半部 生活使得，在来源的使用寿命中，曝光时间必须 由于源活性的减少，要连续扩展。 由于曝光时间与中子的半个月相媲美 损害修复（T1/2），给定剂量的生物学作用将有所不同 在来源的实际寿命中很大程度上。 目标是生产可靠的用户友好的软件工具，允许 医生找到适应给定减少的最佳方法 在源的活动（以及剂量率）中，以便 生物学效应将保持不变。所需的基本信息 是目标细胞的T1/2，以及其他相关的 放射生物学响应参数（alpha/beta）。 在第一阶段，这些将会 确定人类的一个冠状动脉平滑肌细胞系 来源，将编写和评估试点计算机程序 调整暴露时间以获得恒定的生物学有效剂量 随着放射性来源的衰减和治疗时间的变化。 拟议的商业应用 再狭窄使美国卫生保健系统大约为8-2亿 美元/年。 血管辐照可能是一种新技术 提供有效的预防再狭窄，可能有 广泛的应用程序。 因为放射性来源使用的腐烂 它们有用的一生，一种灵活的工具，以生物学为基础 剂量处方调整剂量率的变化将是 基本的。